

# Portomesenteric thrombosis and hypertension in Klippel–Trenaunay syndrome

## Access this article online

<b>Quick Response Code:</b> 	<b>Website:</b> www.avicennajmed.com  <b>DOI:</b> 10.4103/2231-0770.140663
--	--

To The Editor,

In the report entitled “Preoperative splenic artery embolization in Klippel–Trenaunay syndrome (KTS) with massive splenomegaly,” Zhang *et al.* described a 29-year-old woman who was diagnosed with KTS and hypersplenism who underwent splenic artery embolization followed by splenectomy.<sup>[1]</sup> We compliment the authors for their successful management of hypersplenism. Nevertheless, we have a few comments on the etiology of this complication and the diagnosis of KTS.

1. The authors reported that the patient had “noncirrhotic portal hypertension of unknown etiology, complicated by portal vein thrombosis.” The etiology of portal hypertension in KTS is likely related to portomesenteric venous thrombosis. Kulungowski *et al.* reported the association between portomesenteric venous thrombosis and anomalous ectatic mesenteric veins in eight patients with portal hypertension in six patients.<sup>[2]</sup> Four of these patients had typical KTS. The treatment recommendation is prophylactic surgical proximal ligation of the ectatic mesenteric vein
2. The authors described “lymphedema of the lower extremities and cutaneous port-wine stain.” KTS is characterized by fatty overgrowth of a limb, capillary malformation (or port-wine stain), venous malformation and lymphatic malformation.<sup>[3]</sup> Nevertheless, the usual lymphatic spectrum in KTS includes macrocystic and microcystic lymphatic lesions as well as cutaneous vesicles, rather than a typical lymphedema
3. Splenic arteriovenous malformations do not typically occur in patients with KTS. Splenic involvement in KTS is typically limited to lymphatic malformation with or without significant splenomegaly. In addition, portal hypertension may cause splenomegaly

4. In discussing the etiology of coagulopathy in KTS, the authors stated that “thrombocytopenia, in the context of KTS is due to Kasabach–Merritt syndrome secondary to the peripheral vascular malformations.” Thrombocytopenic coagulopathy, more accurately called “Kasabach–Merritt phenomenon” rather than a true syndrome, specifically occurs in kaposiform hemangioendothelioma<sup>[4]</sup> and is not a known feature of KTS.

Though the genetic etiology of KTS has recently been found to be related to somatic mosaic mutations in PIK3CA,<sup>[5]</sup> the reported wide variety of related and unrelated clinical features created a real diagnostic confusion about this uncommon disorder.

## REFERENCES

1. Zhang Z, Dasika NL, Englesbe MJ, Owens SR, Vellody R, Novelli PM, *et al.* Preoperative splenic artery embolization in Klippel–Trenaunay syndrome with massive splenomegaly: A case report. *Avicenna J Med* 2014;4:40-3.
2. Kulungowski AM, Fox VL, Burrows PE, Alomari AI, Fishman SJ. Portomesenteric venous thrombosis associated with rectal venous malformations. *J Pediatr Surg* 2010;45:1221-7.
3. Christison-Lagay ER, Fishman SJ. Vascular anomalies. *Surg Clin North Am* 2006;86:393-425.
4. Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach–Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. *Plast Reconstr Surg* 1997;100:1377-86.
5. Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, *et al.* Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. *Am J Hum Genet* 2012;90:1108-15.

Wibke Uller, Ahmad I. Alomari

Division of Vascular and Interventional Radiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA

### Address for correspondence:

Prof. Ahmad I. Alomari,  
 Division of Vascular and Interventional Radiology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA.  
 E-mail: ahmad.alomari@childrens.harvard.edu

**Cite this article as:** Uller W, Alomari AI. Portomesenteric thrombosis and hypertension in Klippel–Trenaunay syndrome. *Avicenna J Med* 2014;4:106.

**Source of Support:** Nil, **Conflict of Interest:** None declared.